This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
Leukemia Open Access 26 May 2020
-
Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
Cancer Immunology, Immunotherapy Open Access 04 November 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ravandi F, O'Brien S . Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother 2006; 55: 197–209.
Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 2018–2025.
Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N et al. CD4(+)CD25(high) regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 2005; 54: 1–8.
Ziegler SF . FOXP3: of mice and men. Annu Rev Immunol 2006; 24: 209–226.
Chanan-Khan A, Miller KC, Takeshita K, Koryzna A, Donohue K, Bernstein ZP et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 2005; 106: 3348–3352.
Laurenti L, Piccioni P, Tarnani M, De Padua L, Garzia M, Efremov DG et al. Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia. Leuk Res 2007; 31: 253–256.
Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002; 100: 1215–1219.
Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE . TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006; 108: 253–261.
Acknowledgements
This study was supported by a grant from the Scientific Committee KBN (N40203431/1138).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Giannopoulos, K., Schmitt, M., Własiuk, P. et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 22, 222–224 (2008). https://doi.org/10.1038/sj.leu.2404869
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404869
This article is cited by
-
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
Leukemia (2020)
-
A second chance for telomerase reverse transcriptase in anticancer immunotherapy
Nature Reviews Clinical Oncology (2017)
-
Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
Cancer Immunology, Immunotherapy (2017)
-
The targeting of immunosuppressive mechanisms in hematological malignancies
Leukemia (2014)
-
Functional characterization of Foxp3-specific spontaneous immune responses
Leukemia (2013)